IBRX ImmunityBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1326110 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY121.2%
TTM net income YoY-218.3%
TTM EPS YoY-158.5%
Revenue 3-yr CAGR589.9%
Net income 3-yr CAGR—
Margins
Gross margin98.8%
Operating margin-150.2%
Net margin-607.8%
FCF margin-162.5%
EBITDA margin-141.1%
Returns
ROE—
ROA-196.7%
ROIC (approx.)—
Asset turnover0.32x
Leverage & solvency
Liabilities / assets288.0%
Debt / equity—
Current ratio4.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.26x
Accruals ratio-145.7%
Payout ratio—
Capex / revenue5.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $48.84M | $51.24M | $44.21M | $38.28M | $32.06M | $26.43M | $16.52M | $7.55M |
| Cost of revenue | $1.29M | $298,000 | $238,000 | $382,000 | $177,000 | $136,000 | $58,000 | $0 |
| Gross profit | $47.55M | $50.94M | $43.97M | $37.90M | $31.88M | $26.29M | $16.46M | $7.55M |
| R&D expense | — | — | — | — | — | — | — | $35.22M |
| SG&A expense | — | — | — | — | — | — | — | $41.73M |
| Operating income | -$77.99M | -$61.70M | -$69.79M | -$64.68M | -$55.63M | -$71.28M | -$64.43M | -$69.40M |
| Interest expense | — | — | — | $14.84M | $15.26M | $15.47M | $15.31M | $26.02M |
| Pretax income | -$184.56M | -$230.39M | -$632.79M | -$62.09M | -$67.31M | -$92.31M | -$129.90M | -$59.18M |
| Income tax | $0 | $0 | $9,000 | -$135,000 | -$35,000 | $269,000 | -$234,000 | $0 |
| Net income | -$184.55M | -$230.38M | -$632.78M | -$61.94M | -$67.25M | -$92.56M | -$129.65M | -$59.16M |
| EBITDA | -$74.10M | -$57.29M | -$65.41M | -$60.82M | -$52.23M | -$67.89M | -$60.60M | -$65.26M |
| EPS (basic) | -0.17 | -0.22 | -0.62 | — | -0.07 | -0.10 | -0.15 | — |
| EPS (diluted) | -0.18 | -0.22 | -0.62 | — | -0.07 | -0.10 | -0.15 | — |
| Weighted avg. shares (diluted) | 1.06B | 1.05B | 1.03B | — | 946.60M | 888.22M | 853.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $45.08M | $75.67M | $205.19M | $88.33M | $60.24M | $137.66M | $60.66M | $143.43M |
| Short-term investments | $289.25M | $281.70M | $175.69M | $154.48M | $197.57M | $16.00M | $931,000 | $6.38M |
| Receivables | $53.60M | $53.47M | $43.27M | $42.57M | $32.02M | $22.13M | $17.03M | $2.36M |
| Inventory | $6,000 | $1.94M | $547,000 | $910,000 | $6.70M | $6.64M | $8.44M | $8.27M |
| Current assets | $418.79M | $438.98M | $452.95M | $314.88M | $329.50M | $208.13M | $109.16M | $184.59M |
| PP&E, net | $115.05M | $114.22M | $112.78M | $114.26M | $129.60M | $133.00M | $135.27M | $137.09M |
| Goodwill | — | — | $910,000 | $910,000 | $910,000 | $910,000 | $910,000 | $910,000 |
| Intangibles | — | — | $11.91M | $12.99M | $13.53M | $13.51M | $14.02M | $14.53M |
| Total assets | $609.39M | $628.50M | $646.64M | $501.90M | $518.99M | $402.08M | $303.76M | $382.93M |
| Current liabilities | $98.09M | $76.73M | $67.95M | $61.75M | $57.13M | $50.64M | $49.20M | $54.94M |
| Short-term debt | — | — | $884,000 | $1.75M | $2.60M | — | — | $1.25M |
| Total liabilities | $1.75B | $1.67B | $1.52B | $1.00B | $1.04B | $971.89M | $894.24M | $871.06M |
| Shareholders' equity | -$1.15B | -$1.05B | -$870.01M | -$500.47M | -$524.32M | -$570.75M | -$591.43M | -$489.10M |
| Shares outstanding | 1.06B | 1.05B | 1.05B | 1.01B | 984.97M | 915.63M | 853.56M | 852.90M |
| Cash flow statement | ||||||||
| Operating cash flow | -$75.33M | -$66.49M | -$75.36M | -$70.38M | -$68.91M | -$79.75M | -$85.91M | -$85.14M |
| Capital expenditure | $2.93M | $3.52M | $1.78M | $903,000 | $741,000 | $1.08M | $1.12M | $2.11M |
| Free cash flow | -$78.26M | -$70.01M | -$77.14M | -$71.28M | -$69.65M | -$80.83M | -$87.03M | -$87.25M |
| Investing cash flow | -$8.04M | -$107.47M | -$31.65M | $43.57M | -$181.36M | -$16.14M | $4.13M | $9.83M |
| Financing cash flow | $53.03M | $44.44M | $223.93M | $54.89M | $173.52M | $172.81M | -$982,000 | $106.93M |
| Depreciation & amortization | $3.89M | $4.41M | $4.38M | $3.87M | $3.40M | $3.40M | $3.83M | $4.14M |
| Stock-based compensation | $8.72M | $8.52M | $8.17M | $8.75M | $8.88M | $9.65M | $9.54M | $9.04M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.